RxDoctor Payments Data

Erin Burns, DO

Family Medicine · Indianapolis, INNPI 1932462777

Payments from drug & device makers

$677in general payments, 2019–2025

Across 26 payments — averaging $26.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$156
  • AbbVie$102
  • Supernus Pharmaceuticals, Inc.$100
  • GSK$68
  • Dexcom, Inc.$52
  • Novo Nordisk$45
  • plus $155 from 8 others

What the payments were for

  • Food & beverage$677100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$677 in reported general payments places this provider in the 55th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$33,598
Medicare patients
63
Services billed
635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$121,542
Dupixent SyringeDupilumab12$44,495
MounjaroTirzepatide19$28,796
JardianceEmpagliflozin18$23,631
EliquisApixaban11$19,068
TrulicityDulaglutide18$17,387
VyvanseLisdexamfetamine Dimesylate19$6,708
VascepaIcosapent Ethyl11$3,780
Arnuity ElliptaFluticasone Furoate15$3,686
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,388
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$1,091
Mirtazapine11$1,076
ProgesteroneProgesterone, Micronized14$780
Bupropion XlBupropion Hcl27$723
Nystatin32$689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$45$121,54295 claims
Lilly USA, LLCMounjaro, Trulicity$156$46,18337 claims
PfizerEliquis$31$19,06811 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$16$6,70819 claims
GSKArnuity Ellipta$68$3,68615 claims
AbbVieSynthroid$102$48115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →